This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The strategies were: vaccination and drug treatment (albendazole); vaccination only; treatment only; and no intervention. These strategies were considered for two separate populations, school-age children and non-pregnant women of reproductive age.
Location/setting
Brazil/primary care.
Methods

Analytical approach:
A decision model was developed to simulate the potential health states of no hookworm, low-intensity infection, highintensity infection, and death, and the associated infection pathway. The model was populated with data on the risk of infection and the potential benefits of vaccination. The authors stated that the perspective was societal and the time horizon was 20 years.
Effectiveness data:
The effectiveness data included the potential effectiveness of a vaccine, the efficacy of treatment, and the clinical outcomes of hookworm infection. The efficacy of treatment was from a systematic search for published literature in MEDLINE. The key effectiveness estimates were the risk of hookworm infection, the risk of infection being high intensity, anaemia rates, the cure rate with albendazole, the egg reduction rate, and the probability of the vaccine preventing infection.
Monetary benefit and utility valuations:
The disability weights for the disability-adjusted life-years (DALYs) were based on World Health Organization estimates for Brazil.
Measure of benefit:
DALYs were calculated, as the measure of benefit, and they were used to estimate the ratio of cost per DALY gained.
Cost data:
The cost categories were the direct medical cost of the vaccine, and the costs of the drugs and their delivery. These were based on estimates from the published literature. Clinic visits and sick leave costs were excluded; the authors
